somatropin, rDNA origin, for injection

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Growth Disorder

Conditions

Growth Disorder

Trial Timeline

Feb 1, 2001 → Jan 1, 2006

NCT ID

NCT00191074

About somatropin, rDNA origin, for injection

somatropin, rDNA origin, for injection is a phase 3 stage product being developed by Eli Lilly for Growth Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191074. Target conditions include Growth Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Growth Disorder were approved

Approved (11) Terminated (1) Active (9)

✅PEG-somatropinSun PharmaceuticalApproved

✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Saizen + SaizenMerckApproved

✅EverolimusNovartisApproved

✅somatropin + somatropin + somatropinNovo NordiskApproved

✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00191074	Phase 3	Completed	Feb 1, 2001	Jan 1, 2006	Growth Disorder

Competing Products

20 competing products in Growth Disorder

See all competitors

Product	Company	Stage	Hype Score
Somatropin	Eli Lilly	Phase 3	40
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)	Eli Lilly	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
Erlotinib	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
pegylated Somatropin + pegylated Somatropin + Jintropin AQ	Sun Pharmaceutical	Phase 2	35
PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin + PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin	Sun Pharmaceutical	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
Sterile becaplermin gel vs. sterile placebo gel treatment 1	Johnson & Johnson	Pre-clinical	26
ABT-414	AbbVie	Pre-clinical	26
Saizen® A + Saizen® B	Merck	Phase 3	40
Saizen® solution for injection (referred as Saizen®)	Merck	Approved	43
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)	Merck	Phase 3	40
Saizen + Saizen	Merck	Approved	43
Miransertib	Merck	Phase 2	39
Miransertib	Merck	Phase 1/2	24
ARX201 + ARX201 + ARX201	Merck	Phase 2	35